-
Mashup Score: 2The Right to be Forgotten: ESMO Calls on EU Countries to Ensure Equal Financial Rights for Cancer Survivors - 1 year(s) ago
ESMO calls on EU member states to adopt a five-year threshold for cancer survivors’ right to be forgotten when transposing the revised EU Consumer Credits Directive to their national legislationThe Society has been selected as one of the key stakeholders involved in the development of the EU Code of Conduct which seeks to ensure that advances in cancer care are reflected in the commercial practices of financial service providersThe ESMO Patient Advocacy Working Group aims to launch a pan-European campaign to illustrate to decision-makers the life-changing impact of a simple provision already implemented by some member states
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
PURPOSE Successful completion of chemotherapy is critical to improve breast cancer outcomes. Relative dose intensity (RDI), defined as the ratio of chemotherapy delivered to prescribed, is a measure of chemotherapy completion and is associated with cancer mortality. The effect of exercise and eating a healthy diet on RDI is unknown. We conducted a randomized trial of an exercise and nutrition intervention on RDI and pathologic complete response (pCR) in women diagnosed with breast cancer initiating chemotherapy. METHODS One hundred seventy-three women with stage I-III breast cancer were randomly assigned to usual care (UC; n = 86) or a home-based exercise and nutrition intervention with counseling sessions delivered by oncology-certified registered dietitians (n = 87). Chemotherapy dose adjustments and delays and pCR were abstracted from electronic medical records. T-tests and chi-square tests were used to examine the effect of the intervention versus UC on RDI and pCR. RESULTS Partici
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🏃♀️ Exercise and nutrition led to improved diet quality, physical activity, and pCR in women receiving #chemotherapy for #BreastCancer. ➡️ https://t.co/to4MpmrqFs #BCSM @mirwin_yale https://t.co/GvzzRhPxDX
-
-
Mashup Score: 0
The FDA companion diagnostic designation for the FoundationOne CDx and FoundationOne Liquid CDx may improve access to treatment with encorafenib plus binimetinib for those with BRAF V600E-mutated non–small cell lung cancer.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA has granted approval to FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to identify patients with metastatic #NSCLC harboring a BRAF V600E mutation who may be eligible to receive treatment with encorafenib plus binimetinib. https://t.co/figFCUEqI2 https://t.co/oZoJeLr05d
-
-
Mashup Score: 0
Breast cancer patients with obesity may derive less of a benefit from aromatase inhibitors than patients of a “healthy” weight, according to researchers.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Breastcancer patients with obesity may derive less of a benefit from aromatase inhibitors than patients of a “healthy” weight. From @JAMAnetworkopen. With @Cancertheradvsr for #BreastCancerAwarenessMonth. https://t.co/cTa5kKJLWK #BCSM https://t.co/HObzoR8w1h
-
-
Mashup Score: 0Nivolumab/Chemotherapy Leads to OS, PFS Improvements in UC - 1 year(s) ago
Findings from the CheckMate-901 trial demonstrated improvements for the treatment of patients with urothelial carcinoma who received a combination of nivolumab and chemotherapy followed by nivolumab monotherapy.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the CheckMate-901 trial, nivolumab + cisplatin-based chemotherapy, followed by nivolumab monotherapy, showed significant improvements in OS and PFS for patients with cisplatin-eligible unresectable or metastatic urothelial carcinoma. #BLCSM #ESMO23 https://t.co/gU9lfOSvHL
-
-
Mashup Score: 0Lung Cancer Screening in Asia: An Expert Consensus Report - 1 year(s) ago
The incidence and mortality of lung cancer are highest in Asia compared with Europe and USA, with the incidence and mortality rates being 34.4 and 28.1 per 100,000 respectively in East Asia. Diagnosing lung cancer at early stages makes the disease amenable to curative treatment and reduces mortality. In some areas in Asia, limited availability of robust diagnostic tools and treatment modalities, along with variations in specific health care investment and policies, make it necessary to have a more specific approach for screening, early detection, diagnosis, and treatment of patients with lung cancer in Asia compared with the West.
Source: www.jto.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Incidence & mortality of #lungcancer are highest in Asia when compared next to Europe/USA. Asian countries face challenges in implementing low-dose CT screening. Authors suggest strategies to overcome said challenges (discussed in this article). https://t.co/xpJlkb46qA @pan20447 https://t.co/sLMcGs0wPw
-
-
Mashup Score: 1Home Page: ESMO Journals - 1 year(s) ago
Annals of Oncology Vol. 34 Issue 9 Annals of Oncology Vol. 34 Issue 9 Immuno-Oncology and Technology Vol. 19 Immuno-Oncology and Technology Vol. 19 Cancer Treatment Reviews Vol. 119 Cancer Treatment Reviews Vol. 118 Clinical Lymphoma, Myeloma and Leukemia Vol. 23 Issue 8 Clinical Lymphoma, Myeloma and Leukemia Vol. 23 Issue 8 Editor in Chief: Fabrice Andre Impact Factor: 51.769 Publishes research on innovative cancer treatments or translational work related to oncology and precision medicine. Focus on:
Source: www.esmojournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Don’t miss the chance to meet the #ESMOOncologyJournals’ #EditorsinChief at #ESMO23, get your questions answered by them and learn about their vision. @Annals_Oncology @ESMO_Open @esmo_iotech @rdienstmann 🗓️ 22 Oct, 9:15-9:55 CEST, Networking Hub https://t.co/DvFVzlAtUX https://t.co/F2XgIJiRbU
-
-
Mashup Score: 0Moungi G. Bawendi, Louis E. Brus, Alexei I. Ekimov awarded 2023 Nobel Prize in Chemistry for quantum dots - The Cancer Letter - 1 year(s) ago
Moungi G. Bawendi, Louis E. Brus, and Alexei I. Ekimov were jointly awarded the 2023 Nobel Prize in Chemistry for their discovery and development of quantum dots—nanoparticles so tiny that their size determines their properties. These smallest components of nanotechnology now spread their light from televisions and LED lamps, and can also guide surgeons when […]
Source: cancerletter.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Moungi G. Bawendi, Louis E. Brus, Alexei I. Ekimov awarded 2023 @NobelPrize in Chemistry for quantum dots. https://t.co/PKCrbW3u0O https://t.co/musgAMjvmS
-
-
Mashup Score: 1
Cancer immunotherapeutics work by unleashing the power of a patient’s immune system to fight cancer and have emerged as one of the most exciting new approaches to cancer treatment. As of July 31, 2023, at least 23 different cancer immunotherapeutics have been approved by the FDA.
Source: cancerprogressreport.aacr.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Immunotherapeutics have emerged as one of the most exciting new approaches to cancer treatment. Learn more in a special section on Immunotherapy: Pushing the Frontier of Cancer Medicine in the AACR #CancerProgressReport: https://t.co/NyYxgSoplA #CancerResearchSavesLives https://t.co/Co6n6zdCr5
-
-
Mashup Score: 0
In a phase II trial reported in JAMA Oncology, Takahashi et al found that the addition of the ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor berzosertib to topotecan did not improve progression-free survival in patients with relapsed small cell lung cancer (SCLC). However, an overall survival benefit was observed with the addition of berzosertib. In the U.S. multicenter study, 60 patients were randomly assigned 2:1 between December 2019 and December 2022 to receive topotecan at 1.25 mg/m 2
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Addition of Berzosertib to Topotecan in Relapsed SCLC https://t.co/OubJU0zZp0 #LCSM #lungcancer #oncology
-
ESMO has been selected, together w/ other stakeholders, to develop the EU Code of Conduct to guide EU members states towards a fair and uniform implementation of the Right to Be Forgotten for #CancerSurvivors. 👉https://t.co/9Wqt0QX9WJ https://t.co/ddIuKIQUWK